{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:20:52Z","timestamp":1773958852681,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Roche molecular diagnostics"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.lungcan.2019.12.016","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T18:30:46Z","timestamp":1577730646000},"page":"37-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer"],"prefix":"10.1016","volume":"141","author":[{"given":"Eva Boysen Fynboe","family":"Ebert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin Holmskov","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Linnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boe","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Meldgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lungcan.2019.12.016_bib0005","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2019.12.016_bib0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2019.12.016_bib0015","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.lungcan.2019.12.016_bib0020","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2019.12.016_bib0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2019.12.016_bib0030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2019.12.016_bib0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"issue":"27","key":"10.1016\/j.lungcan.2019.12.016_bib0040","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2019.12.016_bib0045","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2019.12.016_bib0050","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2019.12.016_bib0055","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.21037\/jtd.2018.12.18","article-title":"Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives","volume":"11","author":"Herbreteau","year":"2019","journal-title":"J. Thorac. Dis."},{"issue":"2","key":"10.1016\/j.lungcan.2019.12.016_bib0060","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jtho.2015.10.002","article-title":"Strategies to improve outcomes of patients with EGFR-mutant non\u2013small cell lung cancer: review of the literature","volume":"11","author":"Zhou","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"133","key":"10.1016\/j.lungcan.2019.12.016_bib0065","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1183\/09059180.00004614","article-title":"Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas","volume":"23","author":"Cortot","year":"2014","journal-title":"Eur. Respir. Rev."},{"issue":"4","key":"10.1016\/j.lungcan.2019.12.016_bib0070","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtho.2015.12.107","article-title":"Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations","volume":"11","author":"Klughammer","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2019.12.016_bib0075","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2019.12.016_bib0080","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2019.12.016_bib0085","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.18632\/oncotarget.6874","article-title":"Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: korean Lung Cancer consortium (KLCC-12-02)","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.lungcan.2019.12.016_bib0090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cllc.2018.03.015","article-title":"Dynamics of EGFR mutation load in plasma for prediction of treatment response and disease progression in patients with EGFR-mutant lung adenocarcinoma","volume":"19","author":"Taus","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2019.12.016_bib0095","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/JTO.0000000000000443","article-title":"Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma","volume":"10","author":"Sen","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.12.016_bib0100","article-title":"Longitudinal monitoring of somatic genetic alterations in circulating cell\u2010free DNA during treatment with epidermal growth factor receptor\u2013tyrosine kinase inhibitors","author":"Iwama","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2019.12.016_bib0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/annonc\/mdw531","article-title":"Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations","volume":"28","author":"Iwama","year":"2017","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2019.12.016_bib0110","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-14-2594","article-title":"Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy","volume":"21","author":"Mok","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.12.016_bib0115","series-title":"Danish Regions. Danish Regions","year":"2019"},{"key":"10.1016\/j.lungcan.2019.12.016_bib0120","series-title":"(Department of Pathology OUH, Skov, BG (Department of Pathology R. Lung Pathology","author":"Olsen","year":"2019"},{"key":"10.1016\/j.lungcan.2019.12.016_bib0125","series-title":"(Odense University Hospital). Palliative Treatment of Non-small Cell Lung Cancer","author":"Jeppesen","year":"2019"},{"key":"10.1016\/j.lungcan.2019.12.016_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.28964","article-title":"Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib","author":"Sorensen","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2019.12.016_bib0135","series-title":"Cobas EGFR Mutation Test v2. Method Sheet Catalog Number: 07248563190 V 4.0 10\/12\/18","year":"2019"},{"issue":"57","key":"10.1016\/j.lungcan.2019.12.016_bib0140","doi-asserted-by":"crossref","first-page":"31066","DOI":"10.18632\/oncotarget.25779","article-title":"A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations","volume":"9","author":"Demuth","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lungcan.2019.12.016_bib0145","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2019.12.016_bib0150","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.lungcan.2015.10.004","article-title":"EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291","volume":"90","author":"Thress","year":"2015","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2019.12.016_bib0155","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(18)30264-9","article-title":"Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial","volume":"6","author":"Wang","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2019.12.016_bib0160","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/1055-9965.EPI-15-0893","article-title":"Circulating DNA and survival in solid tumors","volume":"25","author":"Oca\u00f1a","year":"2016","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2019.12.016_bib0165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9018","article-title":"Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial","volume":"35","author":"Thress","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2019.12.016_bib0170","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9027","article-title":"Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial","volume":"36","author":"Shepherd","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.12.016_bib0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lungcan.2016.01.024","article-title":"Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib","volume":"94","author":"Winther-Larsen","year":"2016","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2019.12.016_bib0180","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2019.12.016_bib0185","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/JTO.0000000000000643","article-title":"Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients","volume":"10","author":"Marchetti","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.12.016_bib0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2018.10.028","article-title":"Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world study (RealGiDo)","volume":"127","author":"Halmos","year":"2019","journal-title":"Lung Cancer"},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2019.12.016_bib0195","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e21081","article-title":"Impact of tyrosine kinase inhibitor (TKI) dose on outcomes of patients with lung cancer","volume":"36","author":"Miao","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2019.12.016_bib0200","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1002\/cncr.30270","article-title":"Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: implications for targeted therapy development","volume":"122","author":"Lampson","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2019.12.016_bib0205","series-title":"U.S. Food and Drug Administration","year":"2019"},{"key":"10.1016\/j.lungcan.2019.12.016_bib0210","series-title":"Roche Diagnostics","year":"2019"},{"issue":"3","key":"10.1016\/j.lungcan.2019.12.016_bib0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/14737159.2017.1288568","article-title":"Profile of the Roche cobas\u00ae EGFR mutation test v2 for non-small cell lung cancer","volume":"17","author":"Malapelle","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.lungcan.2019.12.016_bib0220","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jtho.2016.05.036","article-title":"ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study","volume":"11","author":"Reck","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2019.12.016_bib0225","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.7150\/thno.16558","article-title":"Cross-platform comparison of four leading technologies for detecting EGFR mutations in circulating tumor DNA from non-small cell lung carcinoma patient plasma","volume":"7","author":"Xu","year":"2017","journal-title":"Theranostics"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219307846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219307846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:34:43Z","timestamp":1759235683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219307846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":45,"alternative-id":["S0169500219307846"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.016","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}